Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Feb 1;5(2):e2148415.
doi: 10.1001/jamanetworkopen.2021.48415.

Molecular and Serologic Investigation of the 2021 COVID-19 Case Surge Among Vaccine Recipients in Mongolia

Naranjargal J Dashdorj  1 , Naranbaatar D Dashdorj  1 , Mitali Mishra  2 , Lisa Danzig  3 , Thomas Briese  2 , W Ian Lipkin  2 , Nischay Mishra  2
Affiliations

Molecular and Serologic Investigation of the 2021 COVID-19 Case Surge Among Vaccine Recipients in Mongolia

Naranjargal J Dashdorj et al. JAMA Netw Open. .

Abstract

This cross-sectional study uses molecular and serologic methods to investigate the 2021 surge in COVID-19 cases among vaccine recipients in Mongolia.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Dr Danzig reported receiving personal fees from the Pandefense Advisory during the conduct of the study. Dr Briese reported receiving grants from the Skoll Foundation and nonfinancial support from the Onom Foundation during the conduct of the study. No other disclosures were reported.

Figures

Figure.
Figure.. COVID-19 Cases in Mongolia, 2020 to 2021
A, Timeline of COVID-19 cases in Mongolia (February 2020 to July 2021). B, Daily new cases in Mongolia (March 2020 to July 2021) with a 7-day moving average of daily new cases (orange line). Through July 5, 2021, 2 doses of vaccine were administered to 1 800 018 individuals in Mongolia as follows: BBIBP-CotV (Sinopharm) was administered to 1 634 152 individuals, ChAdOX1-S (Covishield; Oxford/AstraZeneca) to 108 354, BNT162b2 (Pfizer/BioNTech) to 33 170, and Gam-COVID-Vac (Sputnik V; Russian Direct Investment Fund) to 24 342. Data are from Ritchie et al.
See this image and copyright information in PMC

References

    1. Ritchie H, Mathieu E, Rodés-Guirao L, et al. . Coronavirus pandemic (COVID-19). Accessed October 15, 2021. https://ourworldindata.org/coronavirus
    1. Abdalhamid B, Iwen PC, Wiley MR, Pratt CB, Hinrichs SH. Genome analysis for sequence variants in SARS-CoV-2 among asymptomatic individuals in a long-term care facility. JAMA Netw Open. 2021;4(4):e217939. doi:10.1001/jamanetworkopen.2021.7939 - DOI - PMC - PubMed
    1. Eckhardt CM, Cummings MJ, Rajagopalan KN, et al. . Evaluating the efficacy and safety of human anti-SARS-CoV-2 convalescent plasma in severely ill adults with COVID-19: a structured summary of a study protocol for a randomized controlled trial. Trials. 2020;21(1):499. doi:10.1186/s13063-020-04422-y - DOI - PMC - PubMed
    1. Creech CB, Walker SC, Samuels RJ. SARS-CoV-2 vaccines. JAMA. 2021;325(13):1318-1320. doi:10.1001/jama.2021.3199 - DOI - PubMed
    1. Tada T, Zhou H, Samanovic MI, et al. . Comparison of neutralizing antibody titers elicited by mRNA and adenoviral vector vaccine against SARS-CoV-2 variants. bioRxiv 2021. . doi:10.1101/2021.07.19.452771 - DOI

Publication types

Substances

Supplementary concepts